Skip to main content
SpringerLink
Log in

Intravenous or Sequential Ciprofloxacin Therapy in Hospitalised Patients with a Broad Spectrum of Infections

A Post-Marketing Surveillance Study

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: This study set out to obtain up-to-date information on the efficacy, safety and tolerability of ciprofloxacin as well as the time to improvement and recovery, and to explore data on drug utilisation in hospitalised patients with a special focus on intravenous therapy with ciprofloxacin.

Methods, design and patients: Hospitalised patients with a broad spectrum of infections were included in this non-interventional multicentre study. In order to be included, the patients had to be treated with intravenous ciprofloxacin for a minimum of 2 days. Physicians were advised to pay attention to the contraindications mentioned in the summary of product characteristics. They documented demographic and anamnestic data, the type and severity of the infection, concomitant diseases and medications, the course of clinical and laboratory symptoms, and the treatment. In addition, they rated the overall efficacy of intravenous ciprofloxacin and recorded the time to improvement and recovery. All adverse events were reported.

Results: 1012 hospitalised patients with mild to severe clinical infections were included. Their mean age was 61.5 years (SD 16.7), and 57.4% were males. Intravenous ciprofloxacin was given to 28.7% of patients exclusively and 69.6% started with intravenous ciprofloxacin and were switched later to oral treatment. The majority of patients presented with one defined source of infection (77.9%), mainly located in the respiratory tract (40.2%), the abdomen (21.4%), the urinary tract (14.9%) or the kidney (13.4%). Other infections involved the bones and joints (4.5%) or were classified as sepsis (8.0%); 39.6% of infections were classified as severe. Infection symptoms improved in 86.2% of the patients within 5 days. The overall improvement and recovery rates were 91.9% and 85.8%, respectively. Efficacy of ciprofloxacin was judged as ‘very good’ or ‘good’ in 86.5% of patients. Tolerability was judged as ‘very good’ or ‘good’ in 98.2% of patients. Adverse events occurred rarely and were reported in 2.17% of patients. Seventeen (1.68%) fulfilled the criteria of serious adverse events. In only 0.4% of patients was a relationship between the adverse event and ciprofloxacin treatment suspected.

Conclusions: Intravenous ciprofloxacin is an effective and well tolerated antibacterial treatment in hospitalised patients experiencing a broad spectrum of mild to severe infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Fig. 2
Table V

Similar content being viewed by others

References

  1. Thomson CJ. The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective. J Antimicrob Chemother 1999; 43Suppl. A: 31–40

    Article  PubMed  CAS  Google Scholar 

  2. Campoli-Richards DM, Monk JP, Price A, et al. Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1988; 35: 373–447

    Article  PubMed  CAS  Google Scholar 

  3. Guay DRP. The role of fluoroquinolones. Pharmacotherapy 1992; 12 Suppl.: 76–85

    Google Scholar 

  4. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1996; 51: 1019–74

    Article  PubMed  CAS  Google Scholar 

  5. Torres A, Bauer TT, Leon-Gil C, et al. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000; 55: 1033–9

    Article  PubMed  CAS  Google Scholar 

  6. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. Ann Surg 1996; 223: 303–15

    Article  PubMed  CAS  Google Scholar 

  7. Pankey GA. Multicenter, phase IV evaluation of intravenous ciprofloxacin as initial therapy in patients with lower respiratory tract, urinary tract, and skin/skin structure infections. Clin Ther 1995; 17: 353–65

    Article  PubMed  CAS  Google Scholar 

  8. Gangji D, Jacobs F, de Jonckheer J, et al. Brief report: randomized study of intravenous versus sequential intravenous/oral regimen of ciprofloxacin in the treatment of Gram-negative septicemia. Am J Med 1989; 87Suppl. 5A: 206–8

    Article  Google Scholar 

  9. Mombelli G, Pezzoli R, Pinoja-Lutz G, et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections. Arch Intern Med 1999; 159: 53–8

    Article  PubMed  CAS  Google Scholar 

  10. Caballero M, Bonora V, Calbuig JR, et al. Clinical and microbiological comparison of sequential IV/PO ciprofloxacin (CIP) vs parenteral cefotaxime (CEF) in patients with sepsis [abstract]. In: 7th European Congress of Clinical Microbiology and Infectious Diseases, 1995: 218

  11. Rapp RP, Billeter M, Hatton J, et al. Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. Clin Pharm 1991; 10: 49–55

    PubMed  CAS  Google Scholar 

  12. Vogel F, Bodman KF and the expert commission of the Paul-Ehrlich-Gesellschaft. Empfehlungen zur kalkulierten Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Chemother J 2004; 13: 46–105

    Google Scholar 

  13. Bodman KF, Vogel F. Antimikrobielle Therapie der Sepsis. Empfehlungen einer Arbeitsgruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Chemother J 2001; 10: 43–56

    Google Scholar 

  14. Fish DN. Optimal antimicrobial therapy for sepsis. Am J Health Syst Pharm 2002; 59Suppl. 1: 13–9

    Google Scholar 

  15. American Thoracic Society. Guidelines for the management of adults with hospital acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388–416

    Article  Google Scholar 

  16. Naber KG, Bishop MC, Bjerklund-Johansen TE, et al. European Association of Urology. Guidelines on the management of urinary and male genital tract infections [online]. Available from URL: http://www.uroweb.org/index.php?.structure_id=140 [Accessed 2006 Sep 26]

  17. Ball P. Emergent resistance to ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother 1990; 26Suppl. F: 165–79

    Article  PubMed  Google Scholar 

  18. Grünberg RN. Changes in urinary pathogens and their antibiotic sensitivities, 1971–1992. J Antimicrob Chemother 1994; 33Suppl. A: 1–8

    Article  Google Scholar 

  19. Ewig S, Lorenz J, Müller E. Behandlungskonzepte ambulant erworbener Pneumonien. Deutsches Ärzteblatt 2006; 103: A40–6

    Google Scholar 

  20. Cox CE. Brief report: sequential intravenous and oral ciprofloxacin versus intravenous ceftazidine in the treatment of complicated urinary tract infections. Am J Med 1999; 87Suppl. A: 157–9

    Google Scholar 

  21. Cox CE. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections. Am J Med 1993; 94Suppl. 4A: 82–6

    Google Scholar 

  22. Naber KG. Lomefloxacin versus norfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infections. Int J Antimicrob Agents 1992; 2: 33–7

    Article  PubMed  CAS  Google Scholar 

  23. Schaeffer AJ, Anderson RU. Efficacy and tolerability of norfloxacin vs. ciprofloxacin in complicated urinary tract infection. Urology 1992; 40: 446–9

    Article  PubMed  CAS  Google Scholar 

  24. Fang G, Brennen C, Wagener M, et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother 1991; 35: 1849–5

    Article  PubMed  CAS  Google Scholar 

  25. Boerema JBJ, Wellems FThC, Verheggen WJHM. Ciprofloxacin versus cotrimoxazole in the treatment of patients with complicated urinary tract infections. Drug Invest 1989; 1: 18–23

    Article  Google Scholar 

  26. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000; 232: 254–62

    Article  PubMed  CAS  Google Scholar 

  27. Gentry LO. Review of quinolones in the treatment of infections of the skin and skin structure. J Antimicrob Chemother 1991; 28Suppl. C: 97–110

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This PMS study was supported and funded by Bayer Vital GmbH, Leverkusen, Germany. Dr Dr Landen and Mrs Stauch are employees of Bayer HealthCare; Prof. Dr Koch has no conflicts of interest that are directly relevant to the content of this study. Statistical analysis was performed by TNS Healthcare GmbH, Munich, Germany. Dr Christoph Müller-Löbnitz, Forchheim, Germany helped in the preparation of the manuscript. We thank all the physicians who participated in this study.

Author information

Authors and Affiliations

  1. Kreiskrankenhaus Beeskow, Beeskow, Germany

    H. Koch

  2. Post-Marketing Surveillance, Bayer HealthCare AG, Leverkusen, Germany

    H. Landen & K. Stauch

Authors
  1. H. Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Landen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Stauch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Landen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koch, H., Landen, H. & Stauch, K. Intravenous or Sequential Ciprofloxacin Therapy in Hospitalised Patients with a Broad Spectrum of Infections. Clin. Drug Investig. 26, 645–654 (2006). https://doi.org/10.2165/00044011-200626110-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200626110-00004

Keywords

Search

Navigation